

S

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 September 2001 (13.09.2001)


PCT

(10) International Publication Number
WO 01/66090 A1

- (51) International Patent Classification⁷: A61K 9/14, 9/16, 9/51 (72) Inventor; and
(75) Inventor/Applicant (for US only): REVERCHON, Ernesto [IT/TT]; Corso Garibaldi 33, I-84123 Salerno (IT).
- (21) International Application Number: PCT/CH01/00131
- (22) International Filing Date: 1 March 2001 (01.03.2001)
- (25) Filing Language: English (84) Designated States (national): AU, CA, CN, IL, JP, NZ, SG, US, ZA.
- (26) Publication Language: English (84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).
- (30) Priority Data: 422/00 4 March 2000 (04.03.2000) CH Published:
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (71) Applicant (for all designated States except US): ECO₂? SA [CH/CH]; CH-6805 Mezzovico (CH).

[Continued on next page]

(54) Title: MICRONIZED PHARMACEUTICALS



(57) Abstract: By means of the action of a supercritical fluid (SCF), for example supercritical carbon dioxide (SCCO₂), substances of pharmaceutical use are precipitated in form of amorphous or semicrystalline particles of micrometric or submicrometric dimensions. Said substances would most typically be sulfonamides or sulfones such as Nimesulide, dissolved in an organic solvent such as 1-methyl-2-pyrrolidone (NMP) or dimethylsulfoxide (DMSO). The process parameters are such as to maximise the solubility of the organic solvent in the SCF and minimize the solubility of the substance to be micronized in the SCF. The amorphous or semicrystalline state of the particles so obtained, allow one to enhance the pharmacokinetics of the substance.

WO 01/66090 A1

BEST AVAILABLE COPY



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

BACKGROUND OF THE INVENTION

1.Title

Micronized pharmaceuticals

5

2.Field of the invention

The present invention relates to the production of micronized pharmaceuticals, particularly sulfonamides and sulfones (eg. Nimesulide, N-(4-nitro-2-phenoxy-phenyl)methanesulfonamide, CAS 51803-78-2, Rofecoxib, 4-[4-(methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one, CAS 162011-90-7, Celecoxib, 4-[3-(1,1,1-trifluoromethyl)-5-(4-methylphenyl)-pyrazol-1-yl]-benzensulfonamide, CAS 169590-42-5) characterized by amorphous or semicrystalline particles of micrometric and submicrometric dimensions.

10

15 3. Description of Related Art

Numerous sulfonamides, sulfones and their derivatives possess pharmacological actions which classify them in as diverse therapeutic categories as analgesics, bacteriostatics, antibiotics, antihypertensives, antiinflammatories, antirheumatics, antipyretics and diuretics.

20

Among these there is Nimesulide which is a non steroidal anti inflammatory drug (NSAID) with analgesic and antiinflammatory properties. It is the active ingredient in numerous pharmaceuticals such as Nisulid, Aulin, Flogovital, Mesulid, Nimed, Sulidene. It is slightly soluble in water and possesses a moderate bioavailability. One can partially correct this problem by producing it in form of its micronized sodium salt, by means of spray-drying or milling, in dimensions comprised between 5 μ m and 20 μ m (European Patent EP 937709 A1, 25.08.1999,(Helsinn Healthcare SA)).

25

Nimesulide is a cyclooxygenase inhibitor, as are Rofecoxib (a sulfone) and Celecoxib (a sulfonamide). Cyclooxygenase is an enzyme involved in the synthesis of prostaglandins. Pharmacologic properties are in fact often attributable to a particular SAR (Structure Activity Relationship), and sulfonamide and sulfone functional groups are in effect bioisosteric. Structural similarity is also at the origin of similar

30

chemical and physical properties, and therefore of their behaviour in micronization processes carried out by means of the SAS technique, object of the present invention.

- 5 The pharmacokinetics of these active principles depends not only from their chemical and physical properties but also from the dimensions of the particles which constitute the solid.

The usual industrial synthesis methods produce crystalline solids, which are then subsequently micronizable by physical means (eg. jet milling). This method allows a
10 reduction of the crystal diameter to 4-5 μ m, but with a very wide range in size, in the order of 20-30 μ m. Other techniques utilized to produce micronized powders with diameters of a couple of μ m are: precipitation from liquids, plasma spray, freeze drying and spray drying.

These techniques have numerous disadvantages because they are limited as far as
15 smallest obtainable particle size, they generate rather wide granulometric distributions and create problems associated with thermal stability and solvent residues. The particle size limit affects in turn the solubility and especially the speed of dissolution. This limitation has important consequences regarding the preparation of injectable solutions, the development of new applications for the active ingredient
20 (eg. as an inhalable) and the pharmacokinetics.

With respect to the crystalline state, the amorphous state poses less of a hinderance to interactions between the solvent and the still to be dissolved solid.

The production of an amorphous state entails the solubilization of the substance in a solvent and its subsequent solidification in conditions which prevent crystal
25 formation.

During the course of the last decade micronization techniques based on supercritical fluids have been developed, and these have allowed one to obtain micrometric and submicrometric particles with a controlled granulometric distribution. One of these techniques called Supercritical AntiSolvent (SAS) precipitation is based on the fact
30 that the supercritical fluid insoluble substance one wants to micronize is dissolved in an organic solvent, which is soluble in the supercritical fluid. The organic solution is then brought in contact with the supercritical fluid, into which it swells. The solvent

then passes into the supercritical fluid. During this process the solute initially in the organic solution is released in form of particles. The speed of the process and the extreme dispersion of the precipitating solute preclude the formation of crystals, so that the solid precipitates in form of amorphous particles, which according to the conditions range from several hundred nanometers to several micrometers. The semi-continuous variant of this technique is described by Gallagher et al. (Supercritical fluids Science and Technology, ACS Symp. Series 406, 1989, p. 334), the continuous one by Yeo et al. (Biotech. Bioeng., 41, 341 (1993)), and by Reverchon et al. ((Ind.Eng. Chem. Res., 34, 4087, (1995), Pat. It. ITSA970010 A 19970701 (0.-07.97) and finally the batch one by Debenedetti et al. (EP 0542314A1 (1992)).

The SAS technique has been successfully applied to proteins, explosives, solid propellants, polymers, superconducting ceramic precursors and pharmaceuticals such as antibiotics (eg. amoxycillin) and anti-asthmatics (eg. salbutamol).

The SAS technique has not yet been applied to the sulfonamides and sulfones.

This invention utilizes the SAS technique to produce sulfonamides, sulfones and their derivatives in form of amorphous or semicrystalline particles possessing dimensions between 100 nm and 3µm, for use in the production of pharmaceuticals.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig 1. Description of the apparatus utilized for the precipitation process:

1. Precipitation chamber for the micronized solid
2. Injector utilized for feeding the solution of substance to be micronized, with nozzle to atomize the solution
3. Injector for the supercritical fluid used as antisolvent
4. Porous frit to retain micronized powder and allow outflow of solvent and supercritical fluid utilized as antisolvent
5. Outlet for solvent and supercritical fluid utilized as antisolvent
6. Probe to measure temperature and pressure in the chamber listed under 1

Fig 2. SEM image of the micronized product

The product obtained by means of the SAS technique may be analysed by means of a scanning electron microscope to verify its dimensions, its degree of aggregation and its granulometric distribution. In this image one can see the particles obtained by means of the production method 1.

Enlargement: 50'000 x.

Scale: 1 mm = 40 nm

Fig 3. Granulometric distribution curve

By means of specific software (Sigma Scan 5.0) one obtains the granulometric distribution curve in form of a histogram (% total particles in function of particle diameter) from the SEM image.

Minimum diameter (smallest particle diameter): 121 nm

Maximum diameter (largest particle diameter): 385 nm

Mean diameter: 244 nm

Standard deviation from mean value: 5,3%

70% of the particles possesses a diameter between 190 nm and 300 nm

DESCRIPTION OF THE PREFERRED EMBODIMENTS

According to this invention sulfonamides or sulfones are produced in form of amorphous or semicrystalline micronized powders. One starts from a solution of the given sulfonamide or sulfone dissolved in an organic solvent (eg. dimethylsulfoxide (DMSO), 1-methyl-2-pyrrolidone (NMP), ethanol, acetone , ethyl acetate, dimethylformamide (DMF), etc...).

The apparatus to precipitate the micronized powder is described in Fig. 1. It allows one to perform the SAS technique as described in the literature (Reverchon, Della Porta, Taddeo, Pallado, Stassi, Ind. Eng. Chem Res., 34, 4087, (1995); Reverchon, Celano, Della Porta, Pace, Istituto Nazionale per la FISIT (IT): Pat. It. ITSA970010 A

19970701 (0.-07.97); Reverchon, Celano, Della Porta, J. Mat. Res., Vol. 13, No.2, Feb 1998).

It consists of a precipitation chamber 1, possessing two independent inlets:

- 5 -the injector 2 to feed the solution of the substance to be micronized (solute) in a liquid solvent.
- the injector 3 to feed the supercritical fluid to be used as antisolvent.

The injector 2 has a nozzle at its extremity in order to atomize the solution on its entry into chamber 1. Chamber 1 also has a probe fixed into it in order to measure
10 temperature and pressure in the particle forming region. The flow exiting from injectors 2 and 3 should preferably be parallel and flowing in the same direction as is shown in Fig. 1.

On the bottom of the chamber there is a porous frit, preferably made of sinterized material and having an apparent porosity lying preferably between 50 and 100 μm . It
15 must be able to retain the particles and allow the outflow of the solvent and antisolvent through the outlet 5. The solution (solvent +solute) is fed by a first pump to the precipitation chamber 1, and subsequently atomized (formation of microscopic droplets with diameter 20 to 120 μm) by passage through injector 2 and its nozzle. The very high surface area so obtained enables the interaction between
20 solvent and supercritical fluid, which flows continually into chamber 1 by means of injector 3 which in turn is fed by a second pump. During its solubilization in the supercritical fluid the solvent augments its volume by a factor of between 10 and 100. At the same time the supercritical fluid aids the precipitation of the solute because they are mutually insoluble. The solid deposits itself on the porous frit 4
25 while the solvent and antisolvent are vented from outlet 5. The solvent is subsequently recuperated by allowing the spontaneous evaporation of the supercritical fluid. The feed of solvent and antisolvent by means of independent pumps, the pressurization of the supercritical fluid used as antisolvent, the solvent recovery and the eventual recycling of the supercritical fluid used as antisolvent are
30 all carried out as is customary in supercritical fluid plant technology and as described in the literature (Reverchon, Celano, Dalla Porta, J.Mater. Res., Vol 13, No. 2, Feb 1998).

The micronizing effect depends on the speed of the expansion process and on the affinity the solvent has for the supercritical fluid. The nature of the chosen solvent and antisolvent, the antisolvent pressure and temperature as determined by means of probe 6, the solute concentration in the solution and the ratio between flow rate of solution and antisolvent are the factors that determine the dimensions and granulometric distribution of the particles produced. In the present invention DMSO, NMP, ethanol, ethyl acetate or DMF were utilized as solvents, while carbon dioxide, nitrous oxide, propane, ethylene, water or trifluoromethane in their respective supercritical phase were utilized as antisolvent. Flow rates comprised between 0,1 and 100 ml/min were utilized for the solution. The antisolvent flow rate was comprised between 1000 and 10000 ml/min expressed as gas at STP. The concentration of the solution was comprised between 1 and 20 mg/ml.

The physical state of the obtained product can be analyzed by means of scanning electron microscopy (SEM). The SEM image allows one to verify:

- the amorphous (typically in form of spheres) or crystalline (needles, cubes, or other geometric forms according to the nature of the substance) state
- the degree of aggregation
- the granulometric distribution of the micronized powder by means of a specific software (eg. Sigma Scan).

The information one is able to obtain from the SEM analysis allows one to optimize the process parameters (eg. pressure of supercritical fluid used as antisolvent, precipitation chamber temperature, solution concentration, flow ratio of solution and supercritical fluid used as antisolvent), in order to obtain the desired product characteristics (eg. mean particle diameter, granulometric distribution and degree of particle aggregation).

EXAMPLES

Production example 1.

5 By means of the SAS technique amorphous or semicrystalline Nimesulide particles were produced. The substance was dissolved preferably in 1-methyl-2-pyrrolidone (NMP). The resulting solution should possess a concentration comprised between 0,1 and 100 mg/ml, preferably 10 mg/ml.

The solution is fed into the chamber at a flow rate between 0,1 and 10 ml/min, preferably at 1 ml/min, at a density of 1100 kg/m³, in quantities ranging from 20 to 10 50 ml, preferably 30 ml.

The antisolvent, preferably carbon dioxide, is fed into the chamber at a flow rate comprised between 1000 and 10000 ml(gas STP)/min, preferably at 8000 ml (gas STP)/min and at a pressure between 78 and 400 bar, preferably 85 bar and at a temperature between 30 and 60 °C, preferably 40 °C. The resulting ratio between 15 flow rate of solvent and flow rate of antisolvent is 1,25 E-04. The product is finally washed by passing only antisolvent through the chamber for a period of time ranging from 60 to 100 min, preferably 80 min.

Results:

20 • Yield:

The yield of recovered Nimesulide (300 mg) was higher than 95%.

• Identification based on physical data:

The product collected from the bottom of chamber 1 was analyzed by means of scanning electron microscopy (SEM), with an magnification of 50000 X, resulting 25 in Fig. 2.

One is able to observe the remarkable homogeneity of the particle dimensions and their partial aggregation.

The particle diameter and the granulometric distribution were obtained from the SEM image by means of specific software (Sigma Scan 5.0). The spherical shape 30 of the particles is typical of their amorphous state, as this substance has needle shaped crystals in the crystalline state.

The granulometric distribution curve is shown in Fig. 3 in form of a histogram. It depicts the number of particles (% particles) in function of particle diameter.

The granulometric distribution curve has the following characteristics:

- 5 mean diameter (mean) of 244 nm
- minimum diameter (min) of 121 nm
- maximum diameter (max) of 385 nm

- 10 The standard deviation (S.D.) is 5,3% and 70% of the particles possesses a diameter comprised between 180 and 300 nm.

Production example 2.

- 15 By means of the SAS technique amorphous or semicrystalline Nimesulide particles were produced. The substance was dissolved preferably in 1-methyl-2-pyrrolidone (NMP). The resulting solution should possess a concentration comprised between 0,1 and 100 mg/ml, preferably 10 mg/ml.

The solution is fed into the chamber at a flow rate between 0,1 and 10 ml/min, preferably at 1 ml/min, at a density of 1100 kg/m³, in quantities ranging from 20 to 50 ml, preferably 30 ml.

- 20 The antisolvent, preferably carbon dioxide, is fed into the chamber at a flow rate comprised between 1000 and 10000 ml(gas STP)/min, preferably at 8000 ml (gas STP)/min and at a pressure between 80 and 200 bar, preferably 100 bar and at a temperature between 30 and 60 °C, preferably 40 °C. The resulting ratio between flow rate of solvent and flow rate of antisolvent is 1,25 E-04. The product is finally
- 25 washed by passing only antisolvent through the chamber for a period of time ranging from 60 to 100 min, preferably 60 min.

Results:

- Yield:

The yield of recovered Nimesulide (300 mg) was 93%.

- 30 • Identification based on physical data:

The product collected from the bottom of chamber 1 was analyzed by means of scanning electron microscopy (SEM), with an magnification of 50000 X.

One is able to observe the remarkable homogeneity of the particle dimensions and their partial aggregation.

5 The particle diameter and the granulometric distribution were obtained from the SEM image by means of specific software (Sigma Scan 5.0). The spherical shape of the particles is typical of their amorphous state, as this substance has needle shaped crystals in the crystalline state.

The granulometric distribution curve has the following characteristics:

mean diameter (mean) of 235 nm

10 minimum diameter (min) of 120 nm

maximum diameter (max) of 375 nm

The standard deviation (S.D.) is 5,8% and 70% of the particles possesses a diameter comprised between 180 and 300 nm.

15

CLAIMS

1. Product obtained by means of the micronization of pharmaceutical substances,
5 characterized by solid amorphous and/or semicrystalline particles of micrometric and/or submicrometric dimensions, obtained by the action of a supercritical fluid which functions as an antisolvent.
2. The product of Claim 1, characterized by:
10
 - a) particles possessing a diameter inferior to 4 μm ; and
 - b) a granulometric distribution, expressed as a standard deviation of less than 25%, preferably less than 20% ; and/or
 - c) solid amorphous particles which are loose, partially aggregated or aggregated
- 15 3. The product of Claims 1 and 2, obtained by precipitation induced by the action of a supercritical antisolvent, into which the solvent of the solution containing the substance of interest swells and dissolves
- 20 4. The product of Claims 1 to 3 where the supercritical fluid is supercritical carbon dioxide and/or one of the following: nitrous oxide, propane, ethylene, water and/or trifluoromethane.
- 25 5. The product of Claims 1 to 4 where the solvent is 1-methyl-2-pyrrolidone and/or one of the following: dimethylsulfoxide, ethanol, acetone, ethyl acetate and/or dimethylformamide.
- 30 6. The product of Claims 1 to 5 where the micronized product be:
 - a) Nimesulide, a derivative thereof or another sulfonamide or sulfone, inhibitors of cyclooxygenase (COX 1 and/or COX 2) belonging to the following therapeutic classes: antiinflammatories, antipyretics, analgesics, antirheumatics; and/or

b) sulfonamides or sulfones belonging to the following therapeutic classes : antibiotics, bacteriostatics, antihypertensives and diuretics.

5 7. A procedure in which a supercritical fluid mediated precipitation is used to produce pharmacologically active substances according to Claims 1 to 6

8. The procedure of Claim 7, according to which the substance, preferably a sulfonamide or sulfone, be produced in form of an amorphous and/or
10 semicrystalline micronized powder starting from a solution of the said substance in an organic solvent, preferably dimethylsulfoxide, 1-methyl-2-pyrrolidone, ethanol, ethyl acetate or dimethylformamide

9. The procedure of Claims 7 and 8, where into a chamber is fed:

15 a) a solution of Nimesulide whose concentration ranges from 0,1 to 100 mg/ml, at a flow rate ratio between flow rate of solution and flow rate of antisolvent comprised between 10^{-5} and 10^{-2} ml/min(gas STP); and/or
b) an antisolvent at a pressure of between 78 and 400 bar and at a temperature comprised between 30 and 90 °C.

20

10. An apparatus to produce the product of Claims 1 to 6 or an apparatus performing the procedure according to Claims 7 to 9, characterized by:

a) a precipitation chamber ; and
b) a first injector coupled to a first pump, to deliver the solution; and
25 c) a second injector coupled to second pump, to deliver the supercritical fluid

30

1/3




Fig. 1

2/3




Fig. 2

3/3




Fig. 3

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K9/14 A61K9/16 A61K9/51		International Application No PCT/CH 01/00131
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) WPI Data, PAJ, CHEM ABS Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	WO 00 37169 A (SMITHKLINE BEECHAM) 29 June 2000 (2000-06-29) claims page 1, line 2 - line 12 page 4, line 31 -page 5, line 5 page 5, line 27 -page 6, line 4 page 6, line 18 - line 23 page 18, line 7 - line 9 examples ---	1-8, 10
A	WO 97 14407 A (RESEARCH TRIANGLE PHARMACEUTICALS, U.S.A.) 24 April 1997 (1997-04-24) claims figures --- -/--	1-10
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div>		
* Special categories of cited documents :		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*Z* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center; font-weight: bold;">12 July 2001</div>		Date of mailing of the international search report <div style="text-align: center; font-weight: bold;">20/07/2001</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040. Tx. 31 651 epo nl. Fax: (+31-70) 340-3016		Authorized officer <div style="text-align: center; font-weight: bold;">Scarponi, U</div>

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CH 01/00131

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category -	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 31691 A (UNIVERSITY OF KANSAS) 4 September 1997 (1997-09-04) claims figures 1-3,6 ---	1-10
A	WO 96 29998 A (FIDIA ADVANCED BIOPOLYMERS SRL,IT) 3 October 1996 (1996-10-03) claims ---	1-10
A	EP 0 542 314 A (PRINCETON UNIVERSITY) 19 May 1993 (1993-05-19) cited in the application claims figure 1 -----	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CH 01/00131

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0037169 A	29-06-2000	AU 1876100 A	12-07-2000
WO 9714407 A	24-04-1997	AU 709262 B	26-08-1999
		AU 7461796 A	07-05-1997
		EP 0855906 A	05-08-1998
		JP 11514367 T	07-12-1999
WO 9731691 A	04-09-1997	US 5874029 A	23-02-1999
		US 5833891 A	10-11-1998
		AU 709384 B	26-08-1999
		AU 2193697 A	16-09-1997
		CA 2247900 A	04-09-1997
		EP 0885038 A	23-12-1998
WO 9629998 A	03-10-1996	IT PD950065 A	30-09-1996
		IT PD960021 A	05-08-1997
		AU 695207 B	06-08-1998
		AU 5274996 A	16-10-1996
		CA 2216919 A	03-10-1996
		EP 0817620 A	14-01-1998
EP 542314 A	19-05-1993	US 6063910 A	16-05-2000
		AT 167870 T	15-07-1998
		AU 668367 B	02-05-1996
		AU 2831092 A	20-05-1993
		CA 2083027 A	15-05-1993
		DE 69226064 D	06-08-1998
		DE 69226064 T	29-10-1998
		DK 542314 T	12-04-1999
		ES 2118778 T	01-10-1998
		JP 5293361 A	09-11-1993

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.